ClinicalTrials.gg
CompletedNCT02556177mTBI-phase2Updated Sep 10, 2019Results posted

Advanced MRI Applications for Mild Traumatic Brain Injury-Phase 2

An interventional study of MRI in Concussion and Traumatic Brain Injury, sponsored by GE Healthcare. Completed at 7 sites in United States. Open to participants aged 15 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-09-10.

Sponsored by GE Healthcare · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
477
Allocation
Non-randomized
Ages
15 Years to 50 Years
Sex
All
01

Study summary

This is an open-label, non-randomized, prospective, multi-site, parallel group (segment), hypothesis-generating study designed to collect data that will aid in future scientific and engineering exploration of correlations between clinical neuropsychological assessments and GE Research Pack II advanced MR imaging in mTBI patients. The results are primarily intended for scientific inquiry and engineering development purposes, and may be used in future regulatory submissions.

Read the detailed description

This data-driven study is being conducted for hypothesis generation in population of mild traumatic brain injury (mTBI) patients using advanced applications for magnetic resonance imaging (MRI) developed by the Sponsor, GE Healthcare (GEHC), and corresponding clinical neuropsychological assessments. This data is intended for future use in development of specialized MR acquisition, reconstruction, and processing software intended to identify mTBI biomarkers.

02

Conditions studied

  • Concussion
  • Traumatic Brain Injury

Keywords

  • TBI
  • MR
  • mTBI
  • NFL
  • MRI
03

In context

Brain Concussion

550 studies on the registry are indexed under Brain Concussion; 154 are open to participants now.

This study's enrollment of 477 is above the median of 64 across 376 interventional studies indexed under Brain Concussion.

Browse Brain Concussion studies →

Lead sponsor

GE Healthcare is the lead sponsor of 175 studies on the registry; 20 are open to participants now.

Of its 19 completed or terminated interventional studies of FDA-regulated products, 16 (84%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
15 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects included as mTBI patients (Segment 1) will:

  1. Be aged ≥15 and ≤50 years old at the time of enrollment;
  2. Be diagnosed with mTBI according to the standard diagnostic procedures at the investigational site in a timeframe that meets enrollment criteria for enrollment within 72 hours (Visit 1) or 7±2 days (Visit 3) from injury.
  3. Be capable of sufficiently clear communication and language fluency to allow the subject to provide written informed consent, or assent with parental or guardian consent for minors, and to complete study assessments (as per Section 6.3 - Protection of Vulnerable Subjects) for participation in all parts of the study.

Subjects included as non-mTBI controls (Segment 2) will:

  1. Be aged ≥15 and ≤50 years old at the time of enrollment;
  2. Are of similar characteristics as the mTBI population in terms of gender, age, handedness, educational level, and scanner criteria (as per Section 6.1.1 Enrollment of non-mTBI controls)
  3. Be capable of sufficiently clear communication and language fluency to allow the subject to provide written informed consent, or assent with parental or guardian consent for minors, and to complete study assessments (as per Section 6.3 - Protection of Vulnerable Subjects), for participation in all parts of the study.

Exclusion criteria

Exclusion Criteria:

Subjects will be excluded that have: mTBI

  1. Loss of consciousness (LOC) ≥5 minutes;
  2. Posttraumatic amnesia lasting ≥24 hr following mTBI;
  3. Current or prior (within past 10 years) moderate to severe TBI
  4. Diagnosis of mTBI within the past 6 months;
  5. Epilepsy with recurring seizures in past 10 years;
  6. Drug abuse (except marijuana) in past 10 years based on DAST-10 screening;
  7. Alcohol abuse based on AUDIT-C screening;
  8. Current primary Axis I or II psychiatric disorders, except for disorders classified as minor and not expected to impact study conduct or integrity (as detailed in Appendix C - Screening Axis I/II Disorders):
  9. History of brain mass, neurosurgery, stroke, white matter disease, and/or dementia;
  10. Known cognitive dysfunction or structural brain disease/malformation;
  11. Structural brain injury on prior neuroimaging findings;
  12. Been prescribed antipsychotic/antiepileptic medications;
  13. Unable (such as due to urgent medical care needs) or unwilling to complete study procedures accurately or have any conflict of interest that could affect study results, in the opinion of the investigator;
  14. Contraindications to MRI scanning, including:

    • Current or suspected pregnancy, per site practice;
    • Other conditions that may constitute a hazard to the subject during study participation, per investigator;
    • Inability to comply with any part of the site's MR safety policy.

Subjects will be excluded that have:- non-TBI (controls)

  1. Diagnosis of mTBI within the past 6 months;
  2. Prior (within past 10 years) moderate to severe TBI (GCS \<13);
  3. Epilepsy with recurring seizures in past 10 years;
  4. Drug abuse (except marijuana) in past 10 years based on DAST-10 screening;
  5. Alcohol abuse based on AUDIT-C screening;
  6. Current primary Axis I or II psychiatric disorders, except for disorders classified as minor and not expected to impact study conduct or integrity (as detailed in Appendix C - Screening Axis I/II Disorders):
  7. History of brain mass, neurosurgery, stroke, white matter disease, and/or dementia;
  8. Known cognitive dysfunction or structural brain disease/malformation;
  9. Structural brain injury on prior neuroimaging findings;
  10. Been prescribed antipsychotic/antiepileptic medications;
  11. Unable (such as due to urgent medical care needs) or unwilling to complete study procedures accurately or have any conflict of interest that could affect study results, in the opinion of the investigator;
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
477 participants (actual)

Study arms

  • Active comparator
    mTBI patient group (Segment 1)

    1.5T or 3.0T MRI brain scanning with research sequences at 3 to 4 intervals in the acute period, with psychological cognitive evaluations at each MR visit Patients in the acute period following recent diagnosis of mild traumatic brain injury (mTBI)

    Procedure: MRI

  • Active comparator
    non-TBI patients (Segment 2)

    Control subjects with no recent mild traumatic brain injury. 1.5T or 3.0T MRI brain scanning with research sequences at 3 to 4 intervals in the acute period, with psychological cognitive evaluations at each MR visit

    Procedure: MRI

Interventions

  • ProcedureMRI

    MRI scanning

06

What researchers measure

Primary outcomes

  1. MRI Image Data Sets

    MRI image data sets collected from subjects who completed the study.

    Time frame: Per patient scanning over 3 months

  2. Neuropsychological Assessments

    Neuropsychological assessments collected from subjects who completed the study.

    Time frame: Per patient scanning over 3 months

07

Results

Posted Sep 10, 2019

Participant flow

Participant flow — Overall Study
MilestonemTBI Patient Group (Segment 1)Non-TBI Patients (Segment 2)
Started325152
Completed4291
Not completed28361
Withdrew: Subjects did not complete all 4 visits28361

Outcome measures

PrimaryMRI Image Data Sets

MRI image data sets collected from subjects who completed the study.

Time frame:
Per patient scanning over 3 months
Reported as:
Number · Images collected
MRI Image Data Sets
Images collectedmTBI Patient Group (Segment 1)Non-TBI Patients (Segment 2)
Study Visit 1 images collected79150
Study Visit 2 images collected290111
Study Visit 3 images collected240105
Study Visit 4 images collected218118
Total number of images collected827484
PrimaryNeuropsychological Assessments

Neuropsychological assessments collected from subjects who completed the study.

Time frame:
Per patient scanning over 3 months
Reported as:
Number · Neuropsychological assessments
Neuropsychological Assessments
Neuropsychological assessmentsmTBI Patient Group (Segment 1)Non-TBI Patients (Segment 2)
Visit 1 Neuropsychological assessments84152
Visit 2 Neuropsychological assessments303114
Visit 3 Neuropsychological assessments244107
Visit 4Neuropsychological assessments222119
Total number of Neuropsychological assessments853492

Adverse events

Collected over Each visit lasted approximately 90 minutes.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
mTBI Patient Group (Segment 1)0/325 (0%)0/325 (0%)22/325 (6.8%)
Non-TBI Patients (Segment 2)0/152 (0%)0/152 (0%)1/152 (0.7%)
Most frequent other events
Most frequent other events
EventmTBI Patient Group (Segment 1)Non-TBI Patients (Segment 2)
ClaustrophobiaNervous system disorders7/3251/152
Peripheral Nerve StimulationNervous system disorders5/3250/152
PainGeneral disorders3/3250/152
ConcussionNervous system disorders3/3250/152
HeadacheGeneral disorders2/3250/152
AnxietyPsychiatric disorders1/3250/152
ACL tearMusculoskeletal and connective tissue disorders1/3250/152

Baseline characteristics

Segment 1 consisted of adolescent and adult mTBI patients who recently sustained head injury. Segment 2 consisted of subjects who were enrolled as a control population.

Age, Categorical
Age, Categorical(Participants)mTBI Patient Group (Segment 1)Non-TBI Patients (Segment 2)Total
<=18 years16876244
Between 18 and 65 years14963212
>=65 years000
Sex: Female, Male
Sex: Female, Male(Participants)mTBI Patient Group (Segment 1)Non-TBI Patients (Segment 2)Total
Female14176217
Male17663239
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)mTBI Patient Group (Segment 1)Non-TBI Patients (Segment 2)Total
Count of participants——0
Region of Enrollment
Region of Enrollment(participants)mTBI Patient Group (Segment 1)Non-TBI Patients (Segment 2)Total
United States325152477
08

Study locations

7 sites
  • University of California-San Diego
    San Diego, California 92161, United States
  • University of California San Francisco
    San Francisco, California 94121, United States
  • Universtiy of Miami Health System
    Miami, Florida 33136, United States
  • Hospital for Special Surgery
    New York, New York 10021, United States
  • University of Pittsburgh Medical College
    Pittsburgh, Pennsylvania 15203, United States
  • Houston Methodist Neurological Institute
    Houston, Texas 77030, United States
  • Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
09

References and documents

Publications

  • Gangolli M, Perkins NJ, Marinelli L, Basser PJ, Avram AV. Longitudinal MAP-MRI-based Assessment of Tissue Microstructural Alterations in Acute mTBI. medRxiv [Preprint]. 2026 Apr 9:2026.04.06.26350074. doi: 10.64898/2026.04.06.26350074. PubMed 42388887 ↗
  • Tanwar M, Miller E, Tsiouris AJ, Nguyen J, Agarwal V, Marinelli L, Erdemir GA, Shetty T. White Matter Hyperintensities on High-Resolution 3-T MRI: Frequency in Mild Traumatic Brain Injury and Associations With Clinical Markers-A Prospective Controlled Multicenter Study. AJR Am J Roentgenol. 2025 May;224(5):e2432274. doi: 10.2214/AJR.24.32274. Epub 2025 Feb 19. PubMed 39969142 ↗

Study documents

  • Protocol and statistical analysis plan · Nov 14, 2016

Documents are hosted by the registry — open the source record to download them.

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 10, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02556177
Lead sponsor
GE Healthcare
Collaborators
ICON plc
Responsible party
Sponsor
First posted
Sep 22, 2015
Start date
Nov 2015
Primary completion
Jan 31, 2018
Completion
Jan 31, 2018
Results posted
Sep 10, 2019
Last update
Sep 10, 2019

Study contacts

Victor Miranda, MD
study director · GE Healthcare

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion